AB0064 SERUM TENASCIN-C LEVELS ARE ELEVATED IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS. (June 2019)

• Record Type: Journal Article
• Authors: Hulejova, Hana; Bubova, Kristyna; Prajzlerová, Klára; Husakova, Marketa; Filková, Mária; Tomčík, Michal; Pavelka, Karel; Šenolt, Ladislav
• Is Part Of: Annals of the rheumatic diseases. Volume 78(2019)Supplement 2
• Page Start: 1496
• Page End: 1496
• Publication Date: 2019-06
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2019-eular.6822
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Tenascin-C (TNC) is a pro-inflammatory extracellular matrix glycoprotein that is synthesized in various pathological conditions. TNC induces inflammatory activity and promotes damage of joints. Its expression in adults is restricted to sites of tissue injury, particularly during phases of inflammation and active tissue remodelling. Only a few studies have described elevated serum TNC levels in ankylosing spondylitis (AS) compared to healthy controls (HC). Objectives: The aim of this study was to examine the levels of serum TNC among different axial spondyloarthritis (axSpA) subsets and whether TNC levels are related to disease activity measures or other clinical features. Methods: Sixty-one patients who fulfilled the Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axSpA and twenty age and sex-matched HC were included in this study. Based on imaging, patients were further classified as AS (n = 45) and as nr-axSpA (n = 16). Patients with AS were further divided into two subsets based on the absence (n=22) or presence of syndesmophytes (n=23). TNC serum levels were determined using ELISA. The following data were collected: clinical and laboratory disease activity measures; demographic status; disease-related factors such as the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and CRP levels. Statistical analyses were performed with GraphPad Prism 5.1. The data are presented as the median and interquartile range. Results: TNC serum levels were elevated in axSpA patients (535.3 (457.7-677.2) ng/mL) compared to HC (432.1 (329.1-565.9) ng/mL, p= 0.007). Dividing axSpA into nr-axSpA and AS subsets the difference was observed only between AS patients and HC (535.3 (434.5-677.2) vs. 432.1 (329.1-565.9) ng/mL, p=0.022). TNC serum levels did not correlate with disease activity biomarkers (serum CRP or BASDAI) in patients with axSpA. Although we have not observed correlation between TNC and mSASSS radiographic score, weak correlation with disease subsets was found (r=0.25, p=0.025). Conclusion: We demonstrated here elevated serum TNC levels in patients with axSpA, particularly in those with syndesmophytes, which may suggest its role in bone formation during radiographic stage of the disease. Acknowledgement: This work was supported by MH CR 023728, SVV 260373, AZV - 17-33127A Disclosure of Interests: Hana Hulejova: None declared, Kristyna Bubova: None declared, Klára Prajzlerová: None declared, Marketa Husakova: None declared, Mária Filková: None declared, Michal Tomčík: None declared, Karel Pavelka: None declared, Ladislav Šenolt Grant/research support from: AbbVie, Consultant for: AbbVie, Bristol-Myers Squibb, Celgene Corporation, Merck Sharp and Dohme, Novartis, Pfizer, Roche, UCB, Amgen, Takeda, Speakers bureau: AbbVie, Amgen, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly, Merck Sharp and Dohme, Novartis, Pfizer, Roche, UCB